Pharmaceutical Antitrust

BRIDGEPORT, Conn. – A federal judge in Connecticut granted class certification and preliminary approval of a $54 million proposed settlement in an antitrust case claiming drug makers blocked generic alternatives to the stroke medication Aggrenox.

%d bloggers like this: